Evidence map›Paper›PMID 37632631›Full record

ArticleClinical pharmacokinetics2023

Population Pharmacokinetic Analysis of Follicle-Stimulating Hormone During Ovarian Stimulation: Relation with Weight, Prolactin and Gene Polymorphism in THADA and ADIPOQ.

Xiaowei Zhang, Yu Sui, Lei Yu, Min Zhou, Chong Zhang, Danhua Liu, Xinren Chen, Liqun Yang, Yang Sui

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaowei ZhangNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China. sally00125@163.com.ORCID 0000-0002-9372-7107
Yu SuiNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Lei YuNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Min ZhouNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Chong ZhangNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Danhua LiuNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Xinren ChenNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Liqun YangNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China.
Yang SuiNHC Key Laboratory of Reproductive Health and Medical Genetics, China Medical University, Shenyang, China. suiyang2014@163.com.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPersonalisation strategies of ovarian stimulation for in vitro fertilisation (IVF)/ intracytoplasmic sperm injection (ICSI) treatments using exogenous follicle-stimulating hormone (FSH) have been extensively studied over the past 20 years. This research aimed to develop a FSH population pharmacokinetic (PPK) model taking into account the contribution of gene polymorphisms in Chinese reproductive-age women.

methodsData from 173 patients undergoing GnRH agonist down-regulation long protocols of IVF/ICSI treatment were collected. PPK analysis was subsequently conducted using the nonlinear mixed-effect model (NONMEM) software. Several covariates, including 18 single nucleotide polymorphisms, demographic factors and biological characteristics, were evaluated. The final PPK model was extensively validated using bootstrapping and normalised prediction error distribution, as well as external validation on an independent group of 35 patients.

resultsFSH PPK was accurately described by a one-compartment model with first-order absorption. The typical population value of apparent clearance was estimated to be 0.81 L/h [relative standard errors (RSE) 5.3%] with an inter-individual variability (IIV) of 16.0%. The typical apparent distribution volume was 8.36 L (RSE 9.7%, 59.7% IIV), and the absorption rate constant was estimated to be 0.0444 h

conclusionPPK models of FSH have been developed, which could potentially be used for FSH dosage individualisation in the clinical setting. CLINICAL

trial registrationThis study has been registered with the Chinese Clinical Trials Registry (ChiCTR2100049142).

Indexed as

Follicle Stimulating HormoneProlactinAdiponectinFemaleHumansMaleNeoplasm ProteinsOvulation InductionPolymorphism, Single NucleotideSemenAdiponectinADIPOQ protein, humanFollicle Stimulating HormoneNeoplasm ProteinsProlactinTHADA protein, human

Identifiers

PMID37632631
OpenAlexW4386190872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.